Eisai\u2019s anti-Amyloid \u03b2 antibody “Leqemba\u00ae” generated sales revenue of \u00a529.3 billion in Q1 2026, an increase from \u00a523.1 billion in the same period last year. Key sales performances are shown in the US, Japan, and China. The product is being co-commercialized with Biogen.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4523","jir_company_name":"Eisai Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-07-29","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4523-20260729-01.pdf","jir_short_summary":"Eisai\u2019s anti-Amyloid \u03b2 antibody \"Leqemba\u00ae\" generated sales revenue of \u00a529.3 billion in Q1 2026, an increase from \u00a523.1 billion in the same period last year. Key sales performances are shown in the US, Japan, and China. The product is being co-commercialized with Biogen.","jir_summary":"### Performance Overview\nEisai announced that its anti-Amyloid \u03b2 antibody \"Leqemba\u00ae\" achieved sales revenue of \u00a529.3 billion in Q1 2026. This represents an increase from \u00a523.1 billion in the same period last year and demonstrates sales in key countries including the US, Japan, and China. The US sales reached \u00a515.4 billion, the highest figure, with an increase compared to the same period last year. In China, sales were \u00a54.8 billion, affected by inventory adjustments. The product is scheduled for joint commercialization and promotion with Biogen.\n\n### Future Outlook and Impact for Investors\nEisai plans to lead development and regulatory submissions globally, advancing joint commercialization with Biogen. With expected sales growth in 2026, there is optimism about expanding the anti-Amyloid \u03b2 antibody market. Detailed financial results will be announced at the earnings release scheduled for August 3, 2026. For investors, progress in clinical trials and commercialization, along with long-term growth potential, are points of focus.","jir_financial_highlights":"Sales Revenue: \u00a529.3 billion (YoY +\u00a56.2 billion)\nUS Sales: \u00a515.4 billion (YoY +\u00a56.3 billion)\nJapan Sales: \u00a56.1 billion (YoY +\u00a50.6 billion)","jir_category":"","jir_hashtags":"#Eisai, #IR, #JapanStocks","jir_key_figures":"Sales Revenue: \u00a529.3 billion (YoY +\u00a56.2 billion)\nUS Sales: \u00a515.4 billion (YoY +\u00a56.3 billion)\nJapan Sales: \u00a56.1 billion (YoY +\u00a50.6 billion)","jir_meta_title":"\u3010Eisai\u3011Anti-Amyloid \u03b2 Antibody Sales of \u00a529.3 Billion\uff5cQ1 2026","jir_meta_description":"Eisai's anti-Amyloid \u03b2 antibody \"Leqemba\u00ae\" achieved sales revenue of \u00a529.3 billion in Q1 2026. We explain sales status in key countries and future outlook.","jir_og_title":"\u3010Eisai\u3011Anti-Amyloid \u03b2 Antibody Sales of \u00a529.3 Billion\uff5cQ1 2026","jir_og_description":"Eisai's sales for Q1 2026 are \u00a529.3 billion. Detailed insights into sales achievements in the US, Japan, China, and future prospects.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7482,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-89807","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n